Sale!

Myeloid Tumor Panel NGS Genetic Test

4,400 د.إ

-27%

The Myeloid Tumor Panel NGS (Next-Generation Sequencing) Genetic Test is a comprehensive diagnostic tool offered by DNA Labs in the UAE, designed to identify genetic mutations associated with myeloid cancers. This test is crucial for the accurate diagnosis and personalized treatment planning of conditions such as leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. Utilizing cutting-edge NGS technology, the panel examines multiple genes simultaneously, providing a detailed genetic profile of the tumor. This allows healthcare providers to tailor treatments to the specific genetic makeup of the cancer, potentially improving patient outcomes. The test is priced at 4400 AED, reflecting the advanced technology and the valuable insights it provides into the genetic underpinnings of myeloid tumors. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, patients can expect reliable, accurate, and comprehensive results that can significantly impact their treatment journey.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

Myeloid Tumor Panel NGS Genetic Test

At DNA Labs UAE, we offer the Myeloid Tumor Panel NGS Genetic Test at a cost of AED 4400.0. This test is designed to identify mutations in genes associated with myeloid tumors, including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

Test Details

The Myeloid Tumor Panel NGS Genetic DNA Test is a type of genetic test that analyzes a patient’s DNA for mutations in a panel of genes commonly associated with myeloid tumors. These genes include FLT3, NPM1, IDH1, IDH2, TP53, and others.

By identifying specific mutations in these genes, the test can provide valuable information about a patient’s prognosis and help guide treatment decisions. Certain mutations may indicate a higher risk of disease progression or a greater likelihood of responding to specific therapies.

Test Components and Price

The cost of the Myeloid Tumor Panel NGS Genetic DNA Test is AED 4400.0. The test requires a blood sample or extracted DNA. Alternatively, one drop of blood can be collected on an FTA card for testing.

Report Delivery

The report for the Myeloid Tumor Panel NGS Genetic DNA Test is typically delivered within 3 to 4 weeks.

Test Method

The Myeloid Tumor Panel NGS Genetic DNA Test utilizes next-generation sequencing (NGS) technology to analyze the patient’s DNA for mutations.

Referring Doctor and Test Department

This test is typically referred by an Oncologist and is conducted in the Genetics department.

Pre-Test Information

Prior to the test, it is important to provide the clinical history of the patient who is going for the Myeloid Tumor Panel NGS Genetic DNA Test. Additionally, a Genetic Counselling session may be conducted to draw a pedigree chart of family members affected with ASXL1, ATM, CBL, CDKN2A, CEBPA, CREBBP, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, NF1, NOTCH1, NPM1, NRAS, PDGFRB, PHF6, PTPN11, RAD21, RUNX1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, and WT1 genes.

Conclusion

The Myeloid Tumor Panel NGS Genetic DNA Test is a valuable tool for diagnosing and managing myeloid tumors. By identifying specific mutations in genes associated with these tumors, this test can provide personalized treatment options and improve patient outcomes.

 

Test NameMyeloid tumor panel NGS Genetic DNA Test
Components 
Price4400.0 AED
Sample ConditionBlood or Extracted DNA or One drop Blood on FTA Card
Report Delivery3 to 4 Weeks
MethodNGS Technology
Test typeCancer
DoctorOncologist
Test Department:Genetics
Pre Test InformationClinical History of Patient who is going for Myeloid tumor panel NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ASXL1, ATM, CBL, CDKN2A, CEBPA, CREBBP, DNMT3A, ETV6, EZH2, FLT3, GATA2, HRAS, IDH1, IDH2, JAK2, KIT, KRAS, NF1, NOTCH1, NPM1, NRAS, PDGFRB, PHF6, PTPN11, RAD21, RUNX1, SF3B1, SMC1A, SMC3, SRSF2, STAG2, TET2, TP53, U2AF1, WT1
Test Details

The Myeloid Tumor Panel NGS Genetic DNA Test is a type of genetic test that is used to identify mutations in genes associated with myeloid tumors. Myeloid tumors are a type of cancer that affects the bone marrow and blood cells, and can include acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms.

The test uses next-generation sequencing (NGS) technology to analyze a patient’s DNA for mutations in a panel of genes that are commonly associated with myeloid tumors. These genes include FLT3, NPM1, IDH1, IDH2, TP53, and others.

By identifying specific mutations in these genes, the test can help doctors determine a patient’s prognosis and guide treatment decisions. For example, certain mutations may indicate a higher risk of disease progression or a greater likelihood of responding to specific therapies.

Overall, the Myeloid Tumor Panel NGS Genetic DNA Test is a valuable tool for diagnosing and managing myeloid tumors, and can help improve patient outcomes by providing personalized treatment options.